D
DR. REDDY’S LABORATORIES LTD ADR
NYSE: RDY (Dr. Reddy's Laboratories Ltd)
最近更新时间: 23小时之前14.74
0.01 (0.07%)
| 前收盘价格 | 14.73 |
| 成交量 | 3,713,805 |
| 预期市盈率 (P/E Forward) | 31.64 |
| 价格/销量 (P/S) | 3.45 |
| 股市价格/股市净资产 (P/B) | 3.07 |
| 52周波幅 | |
| 股息率 (DY TTM) | 0.68% |
| 营业毛利率 | 16.99% |
| 营业利益率 (TTM) | 20.50% |
| 稀释每股收益 (EPS TTM) | 0.790 |
| 季度收入增长率 (YOY) | 11.40% |
| 季度盈利增长率 (YOY) | 1.90% |
| 总债务/股东权益 (D/E MRQ) | 13.75% |
| 流动比率 (MRQ) | 1.89 |
| 营业现金流 (OCF TTM) | 52.56 B |
| 杠杆自由现金流 (LFCF TTM) | 14.23 B |
| 资产报酬率 (ROA TTM) | 9.71% |
| 股东权益报酬率 (ROE TTM) | 17.71% |
AIStockmoo 评分
| 价值 30% | 1.7 |
| AI Insight 参考 | NA |
| 相对估值 参考 | 0.5 |
| 财务健康 参考 | 3.6 |
| 时机 30% | 1.4 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 4.0 |
| 技术平均移动指标 参考 | -2.5 |
| 市场情绪 20% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 0.5 |
| 内部交易活动 参考 | NA |
| 机构资金流 参考 | 0.5 |
| 市场环境 | ×0.85 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -4.0% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | -2.9 |
| 最终评分 | 1.10 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Dr. Reddy's Laboratories Ltd | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
| HIMS | - | - | - | 18.72 |
|
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Large Core |
| 机构持股比例 | 14.04% |
该时间范围内无数据。
机构
机构持股比例: 15.69%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 101 | 25,365,764 |
| 减持 | 132 | 22,778,120 |
| 新建仓 | 24 | 1,034,173 |
| 清仓 | 33 | 1,396,905 |
来源：经Nasdaq的SEC 13F申报，最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
| 日期 | 类型 | 细节 |
|---|---|---|
| 26 Oct 2026 | Yahoo Finance |
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets. |
| 23 Oct 2026 | Yahoo Finance |
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
Dr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business. Chief Financial Officer M.V. Narasimham said t… |
| 12 Oct 2026 | Yahoo Finance |
Top Stock Reports for Oracle, American Express & Progressive
Oracle, American Express and Progressive face contrasting challenges and growth drivers, from underperformance to rising expenses, premium growth and strategic investments. |
| 25 Aug 2026 | Yahoo Finance |
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks. |
| 股息率 (DY TTM) | 0.68% |
| 5年平均股息收益率 | 1.25% |
| 股息支付比率 | 11.71% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 30 Jul 2024 | 09 May 2024 | - | 0.4791739 现金 |
| 01 Aug 2022 | 24 May 2022 | 12 Aug 2022 | 0.3784342 现金 |
| 08 Jul 2021 | 16 Jun 2021 | 11 Aug 2021 | 0.3364846 现金 |
| 10 Jul 2020 | 26 Jun 2020 | 17 Aug 2020 | 0.3333635 现金 |
| 12 Jul 2019 | 12 Jun 2019 | 15 Aug 2019 | 0.282229 现金 |
| 13 Jul 2018 | 12 Jun 2018 | 09 Aug 2018 | 0.291977 现金 |
| 13 Jul 2017 | - | 10 Aug 2017 | 0.293922 现金 |
| 14 Jul 2016 | - | 09 Aug 2016 | 0.279468 现金 |
| 08 Jul 2015 | - | 17 Aug 2015 | 0.29292 现金 |
| 01 Aug 2014 | - | 15 Aug 2014 | 0.271545 现金 |
| 10 Jul 2013 | - | 15 Aug 2013 | 0.225329 现金 |
| 27 Jun 2012 | - | 06 Aug 2012 | 0.227636 现金 |
| 29 Jun 2011 | - | 11 Aug 2011 | 0.234654 现金 |
| 30 Jun 2010 | - | 17 Aug 2010 | 0.22126 现金 |
| 02 Jul 2009 | - | 12 Aug 2009 | 0.110398 现金 |
| 03 Jul 2008 | - | 18 Aug 2008 | 0.071056 现金 |
| 06 Jul 2007 | - | 10 Aug 2007 | 0.074322 现金 |
| 07 Jul 2006 | - | 21 Aug 2006 | 0.10725 现金 |
| 07 Jul 2005 | - | 16 Aug 2005 | 0.11475 现金 |
| 15 Jul 2004 | - | 24 Aug 2004 | 0.10766 现金 |
| 07 Aug 2003 | - | 02 Oct 2003 | 0.10925 现金 |
| 08 Aug 2002 | - | 30 Sep 2002 | 0.04618 现金 |
| 20 Nov 2001 | - | 13 Dec 2001 | 0.1042 现金 |
| 显示更多 | |||
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2022 | 0.378 | 1 | 3.66 |
| 2021 | 0.336 | 1 | 2.57 |
| 2020 | 0.333 | 1 | 2.34 |
| 2019 | 0.282 | 1 | 3.48 |
| 2018 | 0.292 | 1 | 3.87 |
| 2017 | 0.294 | 1 | 3.91 |
| 2016 | 0.279 | 1 | 3.09 |
| 2015 | 0.293 | 1 | 3.16 |
| 2014 | 0.272 | 1 | 2.69 |
| 2013 | 0.225 | 1 | 2.75 |
| 2012 | 0.228 | 1 | 3.42 |
| 2011 | 0.235 | 1 | 3.99 |
| 2010 | 0.221 | 1 | 2.99 |
| 2009 | 0.110 | 1 | 2.28 |
| 2008 | 0.071 | 1 | 3.63 |
| 2007 | 0.074 | 1 | 2.05 |
| 2006 | 0.107 | 1 | 2.95 |
| 2005 | 0.115 | 1 | 5.31 |
| 2004 | 0.108 | 1 | 5.43 |
| 2003 | 0.109 | 1 | 3.45 |
| 2002 | 0.046 | 1 | 2.39 |
| 2001 | 0.104 | 1 | 5.50 |
| 显示更多 | |||
投资组合